Leonard S. Schleifer - 05 Apr 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Issuer symbol
REGN
Transactions as of
05 Apr 2022
Net transactions value
-$5,051,269
Form type
4
Filing time
07 Apr 2022, 16:04:19 UTC
Previous filing
04 Apr 2022
Next filing
17 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $3,167,533 -4,461 -24% $710.05 13,831 05 Apr 2022 By Trust F1, F2
transaction REGN Common Stock Sale $1,883,736 -2,653 -19% $710.04 11,178 06 Apr 2022 By Trust F1, F3
holding REGN Common Stock 465,922 05 Apr 2022 Direct
holding REGN Common Stock 200,000 05 Apr 2022 2021 GRAT
holding REGN Common Stock 5,874 05 Apr 2022 By 401(k) Plan
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 Represents volume-weighted average price of sales of 4,461 shares of Company stock on April 5, 2022 at prices ranging from $710.00 to $710.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2022 at each separate price.
F3 Represents volume-weighted average price of sales of 2,653 shares of Company stock on April 6, 2022 at prices ranging from $710.00 to $710.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 6, 2022 at each separate price.